The role of antithrombin III in critical patients in obstetrics.
A preliminary study was conducted to detect significant differences between the inflammatory cytokines network recorded in mild and severe preeclampsia compared with normal pregnancy. 36 patients were divided in two groups: (NP) normal pregnancy and (SPH) Severe Preeclampsia and HELLP syndrome. Inflammatory cytokines (IL 6, TNF, IL 10), Antithrombin III (AT III), Protein C (PC) and Tissue Factor Pathway Inhibitor (TFPI) plasma level and Organ Disfunction modified Score (ODS) were recorded. Results shows a difference (P<0,05 ) for AT III and other markers levels in the two groups and, inside of the SPH group, between Severe preeclampsia patients and HELLP syndrome patients. A correlation was found between coagulation natural inhibitors, specially antithrombin III, and the clinical scores. Performing a Caesarean section did not change these results. Based on results of the study we have designed a monitoring and a treatment protocol in our obstetric and general ICU. A multicentric study is now ongoing to validate the preliminary data on the substitutive treatment with AT III.
Mangione
S
S
Department of Anesthesiology, Intensive Care and Emergency, University of Palermo, Italy.
Giarratano
A
A
D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000627:therapeutic use*; D015415:Biomarkers; D003422:Critical Care; D005260:Female; D006801:Humans; D007744:Obstetric Labor Complications / Q000175:diagnosis / Q000188:drug therapy*; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*
D015415:Biomarkers; D015842:Serine Proteinase Inhibitors; D000990:Antithrombin III